 Single centre, open-label, multiple doses, one-sequence design study in two parallel groups of healthy volunteers: Group A: Pre-treatment with ESL, treatment with ESL and ascending doses of Lamotrigine LMT in last phases; Group B: Pre-treatment with LMT, treatment with LMT and ascending doses of ESL in last phases 